Benefits of whole body vibration training in patients hospitalised for COPD exacerbations - a randomized clinical trial

BMC Pulmonary Medicine

Andreas Rembert Koczulla³  Claus Vogelmeier³  Sabina Janciauskiene²  Klaus Kenn⁴  Silke Filipovic¹  Sandra Apelt¹  Daniel Haid³  Bernd Schmeck³  Maja Franke³  Juliane Fechtel³  Janine Koepke³  Christoph Nell³  Timm Greulich³ 

[1] Physiotherapy Department, University Medical Center Giessen and Marburg, Philipps-University Marburg, Marburg, Germany;Hannover Medical School (MHH) Clinic of Pneumology, Hannover, Germany;Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University, Member of the German Center for Lung Research (DZL), Marburg 35043, Germany;Schön Klinik Berchtesgadener Land, Department of Pulmonology, Schönau am Königssee, Germany

关键词: Pulmonary rehabilitation;    Cytokine biology;    COPD exacerbation;    Exercise;   

Others  :  863055
DOI  :  10.1186/1471-2466-14-60

 received in 2014-03-14, accepted in 2014-03-27,  发布年份 2014

【 摘 要 】

Background

Patients with stable COPD show improvements in exercise capacity and muscular function after the application of whole body vibration. We aimed to evaluate whether this modality added to conventional physiotherapy in exacerbated hospitalised COPD patients would be safe and would improve exercise capacity and quality of life.

Methods

49 hospitalised exacerbated COPD patients were randomized (1:1) to undergo physiotherapy alone or physiotherapy with the addition of whole body vibration. The primary endpoint was the between-group difference of the 6-minute walking test (day of discharge – day of admission). Secondary assessments included chair rising test, quality of life, and serum marker analysis.

Results

Whole body vibration did not cause procedure-related adverse events. Compared to physiotherapy alone, it led to significantly stronger improvements in 6-minute walking test (95.55 ± 76.29 m vs. 6.13 ± 81.65 m; p = 0.007) and St. Georges Respiratory Questionnaire (-6.43 ± 14.25 vs. 5.59 ± 19.15, p = 0.049). Whole body vibration increased the expression of the transcription factor peroxisome proliferator receptor gamma coactivator-1-α and serum levels of irisin, while it decreased serum interleukin-8.

Conclusion

Whole body vibration during hospitalised exacerbations did not cause procedure-related adverse events and induced clinically significant benefits regarding exercise capacity and health-related quality of life that were associated with increased serum levels of irisin, a marker of muscle activity.

Trial registration

German Clinical Trials Register DRKS00005979. Registered 17 March 2014.

【 授权许可】

   
2014 Greulich et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
• [2]Fabbri LM, Rabe KF: From COPD to chronic systemic inflammatory syndrome? Lancet 2007, 370:797-799.
• [3]Mador MJ, Kufel TJ, Pineda LA, Steinwald A, Aggarwal A, Upadhyay AM, Khan MA: Effect of pulmonary rehabilitation on quadriceps fatiguability during exercise. Am J Respir Crit Care Med 2001, 163:930-935.
• [4]Crul T, Testelmans D, Spruit MA, Troosters T, Gosselink R, Geeraerts I, Decramer M, Gayan-Ramirez G: Gene expression profiling in vastus lateralis muscle during an acute exacerbation of COPD. Cell Physiol Biochem 2010, 25:491-500.
• [5]Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J: Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011, (10):CD005305. doi:10.1002/14651858
• [6]Gloeckl R, Heinzelmann I, Baeuerle S, Damm E, Schwedhelm AL, Diril M, Buhrow D, Jerrentrup A, Kenn K: Effects of whole body vibration in patients with chronic obstructive pulmonary disease–a randomized controlled trial. Respir Med 2012, 106:75-83.
• [7]Puente-Maestu L, Lazaro A, Tejedor A, Camano S, Fuentes M, Cuervo M, Navarro BO, Agusti A: Effects of exercise on mitochondrial DNA content in skeletal muscle of patients with COPD. Thorax 2011, 66:121-127.
• [8]Remels AH, Gosker HR, Schrauwen P, Hommelberg PP, Sliwinski P, Polkey M, Galdiz J, Wouters EF, Langen RC, Schols AM: TNF-alpha impairs regulation of muscle oxidative phenotype: implications for cachexia? FASEB J 2010, 24:5052-5062.
• [9]Li J, Dai A, Hu R, Zhu L, Tan S: Positive correlation between PPARgamma/PGC-1alpha and gamma-GCS in lungs of rats and patients with chronic obstructive pulmonary disease. Acta Biochim Biophys Sin (Shanghai) 2010, 42:603-614.
• [10]Tang K, Wagner PD, Breen EC: TNF-alpha-mediated reduction in PGC-1alpha may impair skeletal muscle function after cigarette smoke exposure. J Cell Physiol 2010, 222:320-327.
• [11]Trian T, Benard G, Begueret H, Rossignol R, Girodet PO, Ghosh D, Ousova O, Vernejoux JM, Marthan R, Tunon-de-Lara JM, Berger P: Bronchial smooth muscle remodeling involves calcium-dependent enhanced mitochondrial biogenesis in asthma. J Exp Med 2007, 204:3173-3181.
• [12]Remels AH, Schrauwen P, Broekhuizen R, Willems J, Kersten S, Gosker HR, Schols AM: Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J 2007, 30:245-252.
• [13]Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Bostrom EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Hojlund K, Gygi SP, Spiegelman BM: A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012, 481:463-468.
• [14]Handschin C, Spiegelman BM: The role of exercise and PGC1alpha in inflammation and chronic disease. Nature 2008, 454:463-469.
• [15]Barnes PJ: Emerging pharmacotherapies for COPD. Chest 2008, 134:1278-1286.
• [16]Paredi P, Barnes PJ: The airway vasculature: recent advances and clinical implications. Thorax 2009, 64:444-450.
• [17]Gloeckl R, Marinov B, Pitta F: Practical recommendations for exercise training in patients with COPD. Eur Respir Rev 2013, 22:178-186.
• [18]Brusasco V, Crapo R, Viegi G: [Coming together: the ATS/ERS consensus on clinical pulmonary function testing]. Rev Mal Respir 2007, 24:2S11-2S14.
• [19]Seymour JM, Ward K, Sidhu PS, Puthucheary Z, Steier J, Jolley CJ, Rafferty G, Polkey MI, Moxham J: Ultrasound measurement of rectus femoris cross-sectional area and the relationship with quadriceps strength in COPD. Thorax 2009, 64:418-423.
• [20]ATS: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117.
• [21]Jones PW, Quirk FH, Baveystock CM: The St George’s respiratory questionnaire. Respir Med 1991, 85(Suppl B):25-31.
• [22]Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline LN: Development and first validation of the COPD assessment test. Eur Respir J 2009, 34:648-654.
• [23]Fens N, van Rossum AG, Zanen P, van GB, van Klaveren RJ, Zwinderman AH, Sterk PJ: Subphenotypes of mild-to-moderate COPD by factor and cluster analysis of pulmonary function, CT imaging and breathomics in a population-based survey. COPD 2013, 10:277-285.
• [24]Rietschel E, van KS, Fricke O, Semler O, Schoenau E: Whole body vibration: a new therapeutic approach to improve muscle function in cystic fibrosis? Int J Rehabil Res 2008, 31:253-256.
• [25]Jackson KJ, Merriman HL, Vanderburgh PM, Brahler CJ: Acute effects of whole-body vibration on lower extremity muscle performance in persons with multiple sclerosis. J Neurol Phys Ther 2008, 32:171-176.
• [26]van Nes IJ, Latour H, Schils F, Meijer R, van KA, Geurts AC: Long-term effects of 6-week whole-body vibration on balance recovery and activities of daily living in the postacute phase of stroke: a randomized, controlled trial. Stroke 2006, 37:2331-2335.
• [27]Pleguezuelos E, Perez ME, Guirao L, Samitier B, Costea M, Ortega P, Gonzalez MV, Del Carmen VA, Ovejero L, Moreno E, Miravitlles M: Effects of whole body vibration training in patients with severe COPD. Respirology 2013, 18(6):1028-1034. doi:10.1111/resp.12122
• [28]Troosters T, Probst VS, Crul T, Pitta F, Gayan-Ramirez G, Decramer M, Gosselink R: Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 181:1072-1077.
• [29]Abdellaoui A, Prefaut C, Gouzi F, Couillard A, Coisy-Quivy M, Hugon G, Molinari N, Lafontaine T, Jonquet O, Laoudj-Chenivesse D, Hayot M: Skeletal muscle effects of electrostimulation after COPD exacerbation: a pilot study. Eur Respir J 2011, 38:781-788.
• [30]Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schunemann HJ: Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J 2008, 32:637-643.
• [31]Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, Bouillon R, Decramer M: Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003, 58:752-756.
• [32]Singh S: Respiratory physiotherapy during an acute exacerbation–evidence versus practice. Physiotherapy 2013, 99:93-94.
• [33]Bolton CE, Bevan-Smith EF, Blakey JD, Crowe P, Elkin SL, Garrod R, Greening NJ, Heslop K, Hull JH, Man WD, Morgan MD, Proud D, Roberts CM, Sewell L, Singh SJ, Walker PP, Walmsley S: British thoracic society guideline on pulmonary rehabilitation in adults: accredited by NICE. Thorax 2013, 68(Suppl 2):ii1-ii30.
• [34]Pang MY: Whole body vibration therapy in fracture prevention among adults with chronic disease. World J Orthop 2010, 1:20-25.
• [35]Lira VA, Benton CR, Yan Z, Bonen A: PGC-1alpha regulation by exercise training and its influences on muscle function and insulin sensitivity. Am J Physiol Endocrinol Metab 2010, 299:E145-E161.
• [36]Kelly DP: Medicine. Irisin, light my fire. Science 2012, 336:42-43.